TFF Pharmaceuticals (NASDAQ:TFFP) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative thin film drug delivery platforms. Founded in 2007 and headquartered in Austin, Texas, the company leverages its proprietary Thin Film Freezing (TFF) technology to create rapidly dissolving films and gels designed to enhance the bioavailability and patient convenience of approved active pharmaceutical ingredients. TFFP’s platform aims to address limitations associated with traditional oral, injectable and topical dosage forms by offering targeted, non‐invasive alternatives that can improve onset of action and reduce systemic side effects.
The company’s core activities revolve around the formulation, preclinical and clinical evaluation of multiple product candidates built on its TFF platform. Lead programs include thin film formulations for acute neuropathic and chronic pain management, a nasal film for the acute treatment of migraine headaches, and investigational gels for localized hyperhidrosis (excessive sweating). In addition to in‐house development, TFFP pursues out‐licensing and strategic collaborations to accelerate regulatory filings and commercial scale‐up. The platform also extends to potential ophthalmic and buccal delivery systems, aligning with the company’s goal of addressing a broad range of therapeutic areas through film‐based solutions.
Under the leadership of President and CEO Robert L. Ward, TFF Pharmaceuticals has built a management team with deep expertise in pharmaceutical development, regulatory affairs and commercialization. The board combines academic scientists, industry veterans and seasoned investors who guide corporate strategy, intellectual property management and alliance formation. The company’s research and development efforts are supported by partnerships with contract development and manufacturing organizations (CDMOs) and academic laboratories, ensuring access to specialized manufacturing processes and analytical testing capabilities.
Serving patient populations in the United States and pursuing global collaborations, TFF Pharmaceuticals is positioning itself as a leader in drug delivery innovation. The company continues to advance its pipeline through clinical trials and regulatory interactions, with a focus on product candidates that offer clear differentiation in terms of ease of use, rapid onset and improved pharmacokinetic profiles. As TFFP moves toward potential regulatory approvals, it aims to expand its commercial footprint and deliver novel therapeutic options across multiple markets.
